Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Research Identifies Two New Cell Types in Sjögren’s Syndrome

Lara C. Pullen, PhD  |  January 9, 2017

Two previously unidentified cellular players in the pathogenesis of primary Sjogren’s syndrome (pSS) have been discovered: a regulatory T cell (Prdm1+eTreg) and a helper T cell (Il21+Th1). In the study, researchers also identified the transcriptional signatures of these cells and their differential dependency on the lymphotoxin/LIGHT signaling axis, which may guide future therapeutic interventions…

Rituximab Promising for Dermatitis Herpetiformis

Marilynn Larkin  |  January 6, 2017

NEW YORK—Rituximab may be an effective treatment for recalcitrant dermatitis herpetiformis (DH), according to a recent case study. “DH is an autoimmune blistering disease which is commonly associated with celiac disease and can present with debilitating pruritic blisters on extensor surfaces,” explained Dr. Ron Feldman of Emory University School of Medicine. “The most common treatments…

Cyber Safety in the HIPAA Age

Richard Quinn  |  January 6, 2017

Ready for a cyber checkup? Auditing your health IT policies, safeguarding your hardware and educating your staff on the importance of data security should be routine, according to industry experts…

Top ACR Priorities in 2017 Include Drug Costs, MACRA

Kelly Tyrrell  |  January 4, 2017

With a new federal administration and Republican-controlled Congress taking the helm in 2017, the ACR Government Affairs Committee has identified top legislative and regulatory priorities for the year. “The main priority is going to be helping represent the rheumatology community as Medicare is reformed, because the era of MACRA started Jan. 1,” says Angus Worthing,…

Insurance Subcommittee to the Rescue

Mary Beth Nierengarten  |  January 4, 2017

Concerned about reimbursement for specialty drugs? Wondering if your patient can continue on a prescribed medication despite formulary changes? Unsure how to request a tier exception? No need to face these issues alone. The ACR has a resource that can assist with questions regarding coverage and payment policies for private insurers and Medicare. That resource…

FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling

Michele B. Kaufman, PharmD, BCGP  |  January 4, 2017

The makers of FX006, a steroid injection for treating pain in patients with knee osteoarthritis, have submitted a new drug application to the FDA…

Does Telephone Coaching Enhance Physical Activity Programs?

Arthritis Care & Research  |  January 3, 2017

Health coaching by telephone is increasingly being used to assist in chronic disease self-management. A recent study examined the benefits of simultaneous health coaching via telephone as an addition to a physiotherapist-prescribed home-based physical activity program for patients with knee OA. Although participants receiving additional coaching had a short-term improvement in adherence, changes in pain and function did not differ between the study’s groups at six months…

Liquid Biopsy Provides Insights into Lupus

Lara C. Pullen, PhD  |  January 2, 2017

Microparticles in the blood of SLE patients may be a source of extracellular HMGB1, which is involved in immune response. Researchers found that analysis may be able to determine if the patient is producing dead, dying and activated cells that are important for SLE pathogenesis…

Chart a New Course: A Rheumatologist Talks about Practicing in an Orthopedic Environment

Karen Appold  |  December 30, 2016

Working as a rheumatologist in an orthopedic practice has its own unique challenges, but may result in better patient care, according to Sheeja Francis, MD…

Lesinurad with Allopurinol When Allopurinol Alone Is Insufficient

Arthritis & Rheumatology  |  December 29, 2016

Current guidelines for the long-term management of gout recommend a combination of lifestyle management and/or pharmacotherapy to lower serum UA levels to <6.0 mg/dL in most patients or <5.0 mg/dL in patients with more severe disease. Allopurinol is the most widely used xanthine oxidase inhibitor and is recommended in treatment guidelines as a first-line urate-lowering…

  • « Previous Page
  • 1
  • …
  • 462
  • 463
  • 464
  • 465
  • 466
  • …
  • 820
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences